Recombinant Human Interferon Alpha-2b (IFNα-2b)

Product Information

Part Number: I001

Product Name: Interferon Alpha-2b

Synonyms: IFNα-2b, Interferon alfa-2b

Quantity: 100 µg (2×107 IU)

Description

Interferon alpha-2 (IFNα-2) is a cytokine with antiviral and antiproliferative properties. It consists of three principal subtypes: IFNα-2a, IFNα-2b, and IFNα-2c. Among these, IFNα-2b is the predominant subtype encoded in the human genome.

IFNα-2b binds to its receptor and activates the JAK-STAT signaling pathway, stimulating the expression of host genes responsible for antiviral activity.

IFNα-2b has been used therapeutically in the treatment of several diseases including:

• Hepatitis B

• Hepatitis C

• Melanoma

• Kaposi’s sarcoma

• Chronic myeloid leukemia

• Hemangioblastoma

The combination therapy of IFNα-2b with ribavirin, a viral replication inhibitor, has become a standard treatment for chronic hepatitis C virus infection.

Source

Recombinant protein produced in Escherichia coli (E. coli).

The recombinant molecule does not contain any fusion tags.

Molecular Characteristics

Protein length: 166 amino acids (including the N-terminal methionine)

Calculated molecular weight: 19,400 Da

SDS-PAGE migration: Approximately 19 kDa under both reducing (DTT) and non

reducing conditions

Product Specifications

Concentration: 1.0 mg/mL after reconstitution in 100 µL sterile water

Formulation: Lyophilized from sterile PBS, pH 7.4

Purity: ≥97% (SDS-PAGE, SEC-HPLC and RP-HPLC)

Endotoxin Level: <0.1 EU/µg protein (Pyrosate® Kit; Associates of Cape Cod)

Reconstitution

Reconstitute the lyophilized protein with 100 µL sterile water.

Further dilutions should be prepared using culture medium containing 5% fetal bovine serum (FBS).

Shipping

Shipped at ambient temperature.

Storage

Store at 2–8 °C.

For long-term storage, keep at −20 °C.

Handling

Avoid repeated freeze–thaw cycles.

After reconstitution, prepare aliquots and store at −20 °C.

Quality Control

Purity

95% as determined by SDS-PAGE and RP-HPLC.

Biological Activity

The antiviral activity of IFNα-2b is determined according to the method described by Pestka and Baron (1981), based on its ability to inhibit the cytopathic effect produced by Mengo virus in HEp-2 cells (human laryngeal carcinoma cell line, ATCC No. CCL-23).

The specific activity of IFNα-2b is approximately: 2 x 108 UI/mg

when calibrated against the WHO IS for IFNα-2b (NIBSC code 95/566).

Amino Acid Sequence (166 aa)

MCDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE